## We claim:

1. A method of treating metastatic tumors in a subject, which method comprises:

administering to a subject afflicted by metastatic tumors effective amounts of one or more photosensitizer and one or more immuno-adjuvant, and irradiating said subject with light absorbed by said one or more photosensitizer, wherein said method is photochemical mediated photodynamic therapy (PDT).

2. A method of preventing or inhibiting the development of metastatic tumors in a subject, which method comprises:

administering to a subject at risk for developing metastatic tumors effective amounts of one or more photosensitizer and one or more immuno-adjuvant, and irradiating said subject with light absorbed by said one or more photosensitizer.

15

10

3. A method of treating a primary tumor in a subject, which method comprises:

administering to a subject clinically diagnosed with a primary tumor effective amounts of one or more photosensitizer and one or more immuno-adjuvant, and irradiating said subject with light absorbed by said one or more photosensitizer.

20

- 4. The method of claim 2 wherein said subject has previously undergone cancer or tumor therapy.
- 5. The method of claim 1 wherein said effective amount of one or more photosensitizer is in the range of 0.05 to 10 mg/kg.

- 6. The method of claim 5 wherein said effective amount of one or more photosensitizer is in the range of 0.05 to 1 mg/kg.
- 7. The method of claim 5 wherein said effective amount of one or more photosensitizer is in the range of 1 to 10 mg/kg.
  - 8. The method of claim 1 wherein said one or more photosensitizer is administered intravenously and said one or more immuno-adjuvant is administered by injection into tumors after irradiation.

10

- 9. The method of claim 1 wherein said irradiation is localized to the tumors.
- 10. The method of claim 2 wherein said one or more photosensitizer is administered intravenously or intratumorally.

15

11. The method of claim 1 wherein said one or more photosensitizer is administered, and the subject irradiated, before administration of said one or more immuno-adjuvant.

20

- 12. The method of claim 1 wherein said one or more immuno-adjuvant is administered systemically.
- 13. The method of claim 1 wherein said one or more photosensitizer is a benzoporphyrin derivative (BPD) or a green porphyrin.

25

14. The method of claim 13 wherein the BPD is BPD-MA, EA6, or B3.

- 15. The method of claim 1 further comprising an additional irradiation, before irradiation with light absorbed by said one or more photosensitizer, with light of a wavelength which improves penetration of the absorbed light.
- 5 16. The method of claim 1 wherein said one or more immuno-adjuvant comprises mycobacterial cell wall skeleton and/or lipid A from a gram negative bacterium.
  - 17. The method of claim 16 wherein said lipid A is de-3-O-acylated lipid A.

10

- 18. The method of claim 8 further comprising additional systemic administration of immuno-adjuvant to said subject.
- 19. The method of claim 18 wherein said additional systemic administration occurs at least from 1-3 times and occurs at an interval of about two weeks.
  - 20. The method of claim 1 further comprising at least 1-3 repeats of the administering and irradiating steps.
- 20 21. The method of claim 14 wherein said BPD is BPD-MA.
  - 22. A pharmaceutical composition to treat, prevent, or inhibit the development of, metastatic tumors, said composition comprising:
- a photosensitizer and an immuno-adjuvant in amounts effective to treat, prevent, or inhibit the development of, metastatic tumors, and
  - a pharmaceutically acceptable carrier or excipient.

first first 1971 fig. fig. fig. fig. 1971 fig. first first other stand and first first other

- 23. The composition of claim 22 wherein the photosensitizer is a BPD or a green porphyrin.
  - 24. The composition of claim 23 which is a liposomal formulation.

5

- 25. The composition of claim 23 wherein the BPD is BPD-MA, EA6, or B3.
- 26. The composition of claim 23 wherein said immuno-adjuvant comprises mycobacterial cell wall skeleton and lipid A from a gram negative bacterium.

10

27. The composition of claim 26 wherein said lipid A is de-3-O-acylated lipid A.